Brief: Theseus Pharma Announces Business Highlights And Reports Fourth Quarter And Full Year 2022 Financial Results

Theseus Pharmaceuticals

09/03/2023 12:41

March 9 (Reuters) - Theseus Pharmaceuticals Inc  THRX.O :
    * THESEUS PHARMACEUTICALS ANNOUNCES BUSINESS HIGHLIGHTS AND
REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
    * THESEUS PHARMACEUTICALS INC - -630 PHASE 1 PRELIMINARY
DOSE-ESCALATION DATA ANTICIPATED IN Q2 2023
    * THESEUS PHARMACEUTICALS INC -
    * THESEUS PHARMACEUTICALS INC - IND SUBMISSION EXPECTED IN
Q4 2023
FOR -349 IN EGFR-MUTANT NSCLC
    * THESEUS PHARMACEUTICALS INC - CURRENT CASH RUNWAY
PROJECTED INTO
Q3 2025
    * THESEUS - BCR-ABL PRIORITIZED AS THIRD DEVELOPMENT PROGRAM
FOR
PATIENTS WITH CML AND PH+ ALL; DEVELOPMENT CANDIDATE NOMINATION
EXPECTED BY EARLY 2024
    * THESEUS - AS OF DEC 31, 2022, CO HAD CASH, CASH
EQUIVALENTS, &
MARKETABLE SECURITIES OF $211.8 MILLION, AS COMPARED TO $244.7
MILLION AS OF DECEMBER 31, 2021

Source text for Eikon:  ID:nPn4TGMP9a 
Further company coverage:  THRX.O 

 ((Reuters.Briefs@thomsonreuters.com;;))